Company profile ALLO

Allogene Therapeutics Inc
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-po...sitioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le Show More
Quarter analysis & expected interestLast update: February 08 2024 14:25:17.

After 39 days of this quarter the interest is at 7.0. Based on that we can calculate that during remaining 52 days it will total up to 16.0.
Allogene Therapeutics expected interest is significantly lower compared to previous quarter (-82.8%) and same quarter last year (-81.2%).

YearQ1Q2Q3Q4
201954
42
-22.2% QoQ
67
59.5% QoQ
61
-9.0% QoQ
2020 186
244.4% YoY 204.9% QoQ
119
183.3% YoY -36.0% QoQ
64
-4.5% YoY -46.2% QoQ
60
-1.6% YoY -6.2% QoQ
2021 58
-68.8% YoY -3.3% QoQ
74
-37.8% YoY 27.6% QoQ
49
-23.4% YoY -33.8% QoQ
78
30.0% YoY 59.2% QoQ
2022 113
94.8% YoY 44.9% QoQ
69
-6.8% YoY -38.9% QoQ
52
6.1% YoY -24.6% QoQ
68
-12.8% YoY 30.8% QoQ
2023 85
-24.8% YoY 25.0% QoQ
109
58.0% YoY 28.2% QoQ
97
86.5% YoY -11.0% QoQ
93
36.8% YoY -4.1% QoQ
2024 7
-91.8% YoY -92.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Allogene Therapeutics search interestLast update: February 08 2024 14:25:17.
Correlation coefficient between keyword and revenue is -0.28
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:25:18.

The average 5 years interest of Allogene Therapeutics was 6.15 per week.
The last year interest of Allogene Therapeutics compared to the last 5 years has changed by 6.02%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 28.85%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics UCART19 to provide analysis

Correlation between past revenue and Allogene Therapeutics UCART19 search interest

There is not enough data for Allogene Therapeutics UCART19 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics UCART19 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics ALLO-501 to provide analysis

Correlation between past revenue and Allogene Therapeutics ALLO-501 search interest

There is not enough data for Allogene Therapeutics ALLO-501 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics ALLO-501 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics ALLO-501A to provide analysis

Correlation between past revenue and Allogene Therapeutics ALLO-501A search interest

There is not enough data for Allogene Therapeutics ALLO-501A to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics ALLO-501A to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics ALLO-715 to provide analysis

Correlation between past revenue and Allogene Therapeutics ALLO-715 search interest

There is not enough data for Allogene Therapeutics ALLO-715 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics ALLO-715 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics ALLO-605 to provide analysis

Correlation between past revenue and Allogene Therapeutics ALLO-605 search interest

There is not enough data for Allogene Therapeutics ALLO-605 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics ALLO-605 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics ALLO-647 to provide analysis

Correlation between past revenue and Allogene Therapeutics ALLO-647 search interest

There is not enough data for Allogene Therapeutics ALLO-647 to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics ALLO-647 to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics jobs to provide analysis

Correlation between past revenue and Allogene Therapeutics jobs search interest

There is not enough data for Allogene Therapeutics jobs to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics jobs to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Allogene Therapeutics reviews to provide analysis

Correlation between past revenue and Allogene Therapeutics reviews search interest

There is not enough data for Allogene Therapeutics reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Allogene Therapeutics reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 14:25:25.

After 39 days of this quarter the interest is at 30.0. Based on that we can calculate that during remaining 52 days it will total up to 70.0.
Allogene Therapeutics -stock -company expected interest is significantly lower compared to previous quarter (-49.3%) and same quarter last year (-56.0%).

YearQ1Q2Q3Q4
201977
134
74.0% QoQ
158
17.9% QoQ
108
-31.6% QoQ
2020 250
224.7% YoY 131.5% QoQ
163
21.6% YoY -34.8% QoQ
128
-19.0% YoY -21.5% QoQ
56
-48.1% YoY -56.2% QoQ
2021 129
-48.4% YoY 130.4% QoQ
115
-29.4% YoY -10.9% QoQ
105
-18.0% YoY -8.7% QoQ
198
253.6% YoY 88.6% QoQ
2022 202
56.6% YoY 2.0% QoQ
160
39.1% YoY -20.8% QoQ
114
8.6% YoY -28.8% QoQ
131
-33.8% YoY 14.9% QoQ
2023 159
-21.3% YoY 21.4% QoQ
195
21.9% YoY 22.6% QoQ
112
-1.8% YoY -42.6% QoQ
138
5.3% YoY 23.2% QoQ
2024 30
-81.1% YoY -78.3% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Allogene Therapeutics -stock -company search interestLast update: February 08 2024 14:25:25.
Correlation coefficient between keyword and revenue is -0.2
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 14:25:28.

The average 5 years interest of Allogene Therapeutics -stock -company was 10.97 per week.
The last year interest of Allogene Therapeutics -stock -company compared to the last 5 years has changed by -3.19%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by 2.61%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for ALLO
Earnings date: 2024-02-28 After close
Company name: Allogene Therapeutics Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-13T20:02:00Z

GlobeNewswire
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

2026-05-06T12:30:00Z

GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

2026-04-21T12:30:00Z

GlobeNewswire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

2026-04-20T12:30:00Z

GlobeNewswire
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

2026-04-16T20:01:00Z

GlobeNewswire
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

2026-04-16T15:05:15Z

Analyst Upgrades
JP Morgan Upgrades Allogene Therapeutics to Neutral

2026-04-16T11:02:43Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $11

2026-04-15T18:40:09Z

Analyst Upgrades
Jefferies Maintains Buy on Allogene Therapeutics, Raises Price Target to $10

2026-04-15T12:30:00Z

GlobeNewswire
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

2026-04-15T01:50:00Z

GlobeNewswire
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

2026-04-14T15:42:49Z

Analyst Upgrades
Bernstein Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

2026-04-14T15:37:43Z

Analyst Upgrades
Argus Research Maintains Market Perform on Allogene Therapeutics, Raises Price Target to $3.85

2026-04-14T12:27:11Z

Analyst Upgrades
Citizens Maintains Market Outperform on Allogene Therapeutics, Raises Price Target to $8

2026-04-14T11:48:23Z

Analyst Upgrades
Baird Maintains Outperform on Allogene Therapeutics, Raises Price Target to $9

2026-04-14T11:07:47Z

Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Raises Price Target to $12